UNSPSC 51351801: Norvinisterone

This classification denotes a therapeutic progestin with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q843V12Q0, chemically known as 19-nor-17-alpha-pregna-4,20-dien-3-one, 17-hydroxy- but generally known as norvinisterone, which bears US NIH Compound Identifier 65588. European Medicines Agency schedules Norvinisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09381MIG.

UNSPSC 51351801 Norvinisterone is a Commodity code covering pharmaceutical active ingredients and related chemical compounds supplied to state and local health systems and institutional buyers through cooperative purchasing frameworks. State and local governments procure under this code primarily through multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions to achieve volume-based pricing and standardized supply chain agreements. The work involves establishing framework agreements with pharmaceutical manufacturers and suppliers to provide generic pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients meeting FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) certification. Issuing bodies include state procurement offices administering cooperative purchasing vehicles, state health departments, and affiliated purchasing alliances representing multiple member states and localities. Vendors must maintain relationships with authorized pharmaceutical wholesalers, provide detailed product data including National Drug Codes (NDC), SKUs, and Universal Product Codes (UPC), and accept pricing structures ranging from flat price to WAC-minus formulas with administrative fee pass-throughs. Insurance requirements typically include commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The proposal deadline was March 26, 2026, with a questions cutoff on February 18, 2026; awarded vendors would become effective July 1, 2026 after products became available in the marketplace by May 15, 2026. Evaluation weighting heavily favored price competitiveness at 75 percent, with smaller weights assigned to fixed pricing (10 percent), compliance with administrative fee data format and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). The contract term runs two years for new responders with optional MMCAP extensions, or aligns with existing agreement expiration dates through June 30, 2028 for incumbent amendments. No specific dollar amounts or set-aside designations were disclosed in the solicitation materials.